health care Stocks

4Dmedical Limited specializes in developing and commercializing state-of-the-art respiratory imaging technology, notably its XV Lung Ventilation Analysis Software (XV LVAS). This non-invasive technology provides quantitative and visual assessments of regional lung function, aiming to improve the diagnosis and management of various respiratory conditions. The company primarily operates in Australia and is aggressively expanding its presence in the large US healthcare market.

Lumos Diagnostics Holdings Limited (ASX: LDX) is an Australian-based company developing and commercialising rapid, point-of-care (POC) diagnostic tests for infectious diseases. Their flagship product, FebriDx, aims to differentiate bacterial from viral infections within minutes, assisting clinicians in reducing unnecessary antibiotic prescriptions. Lumos operates globally with R&D and manufacturing facilities in the US, targeting healthcare markets across North America, Europe, and Australia.

Nyrada Inc. is an Australian-based biotechnology company focused on the development of novel neuroprotectants and cardiovascular therapeutics. The company's lead programs target significant medical needs such as traumatic brain injury, stroke, and certain cardiovascular diseases, with drug candidates in pre-clinical and early clinical development phases. Nyrada operates primarily in the research and development sector, aiming to develop first-in-class treatments.

Starpharma Holdings Limited (SPL) is an Australian biotech company specializing in pharmaceuticals and life sciences. Headquartered in Melbourne, SPL operates globally, focusing on drug delivery technologies, with its lead product being Dendrimers, particularly the proprietary DuraGel technology for enhancing drug efficacy and safety. Key products include clinical-stage oncology and infectious disease treatments.

Artrya Limited is an Australian medical technology company that develops and commercializes AI-powered software for the diagnosis of coronary artery disease. Its flagship product, Salix, analyzes cardiac CT scans to identify stenosis and vulnerable plaque, aiming to improve diagnostic accuracy and prevent heart attacks. The company targets cardiologists, radiologists, and hospitals globally, with key regulatory approvals in Australia, Europe, and the USA.

Dorsavi Ltd (ASX: DVL) is an Australian-based company that develops wearable sensor technology and software solutions for analyzing human movement. Their proprietary technology provides objective data for injury prevention, performance enhancement, and clinical rehabilitation across elite sports, occupational health, and healthcare sectors, operating globally.

Rhythm Biosciences Limited (ASX: RHY) is an Australian medical diagnostics company focused on developing and commercialising its lead product, ColoSTAT, a simple blood test for the early detection of colorectal cancer. The company aims to provide a more accessible and non-invasive screening solution globally, primarily targeting markets in Australia, Europe, and the USA.

Ratura Oncology Ltd (ASX: RAC) is an Australian-listed biotechnology company focused on the discovery, development, and commercialization of novel therapeutic candidates for the treatment of various cancers. Operating primarily in the preclinical and clinical trial phases, the company aims to address unmet medical needs within oncology by advancing its pipeline of drug candidates.

Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.

Heramed Limited (ASX: HMD) is an Australian-Israeli digital health company focused on remote pregnancy monitoring solutions. Its flagship product, HeraBEAT, is a medical-grade, CE-marked, and TGA-approved device enabling expectant mothers to monitor vital signs and fetal heart rate from home. The company operates globally by partnering with healthcare providers and health systems to integrate its technology into patient care pathways.

Island Pharmaceuticals Limited (ASX: ILA) is an early-stage Australian biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions in the pharmaceuticals and biotechnology sector. Primarily operating in Australia, with potential for global clinical trials, ILA is currently pre-revenue, concentrating on advancing its lead compound through clinical phases, targeting specific unmet medical needs. Key products/services include its proprietary drug candidate for [undisclosed target disease/condition, assuming specificity not publicly available, thus a placeholder].

Blinklab Limited (ASX: BB1) is a Australian health tech company, operating in the health care equipment and services sector. Specific to the Australian market, it develops innovative, non-invasive diagnostic devices for early detection of ophthalmological conditions, leveraging AI-driven analysis. Key product is 'EyeSightAI', targeting the Australian healthcare system and private clinics.

Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis.

Apiam Animal Health Limited is a leading provider of veterinary services, operating a network of clinics predominantly across regional and rural Australia. The company offers a comprehensive range of veterinary care for companion animals, equine, and livestock, along with related products and services.

Nanollose Limited (ASX: NC6) is an Australia-based biotechnology company focused on developing novel, sustainable biomaterials. The company operates primarily in Australia and is known for its innovative approach to producing cellulose from organic waste, targeting applications in health care, textiles, and more. Key products include its patented nanocellulose materials for wound care and cosmetic applications.

Cambium Bio Limited is an Australian clinical-stage biotechnology company focused on developing novel regenerative medicine therapies. Its lead program is centered on a proprietary cell-based treatment for osteoarthritis, aiming to repair damaged cartilage and reduce inflammation. The company's operations are primarily focused on preclinical research and advancing its lead candidate into early-stage human clinical trials.

Atomo Diagnostics Limited (ASX: AT1) is an Australian medical device company specialising in the design, manufacture, and commercialisation of user-friendly rapid diagnostic test (RDT) devices. Its patented AtomoRapid platform simplifies blood-based point-of-care and self-test applications, aiming to improve testing accuracy and accessibility for various infectious diseases globally.

Pacific Edge Limited (ASX: PEB) is a New Zealand-based healthcare company specialising in the development and commercialisation of non-invasive diagnostic tests for the early detection and management of cancer. Its flagship product suite, Cxbladder, focuses on bladder cancer detection and surveillance, primarily targeting the significant US market alongside New Zealand and other international regions.

Vectus Biosystems Limited (ASX: VBS) is an Australian biotechnology company dedicated to the discovery and development of novel small molecule drugs for fibrotic diseases. Their primary focus is on conditions like heart failure and kidney fibrosis, leveraging their expertise in the Renin-Angiotensin-Aldosterone System (RAAS) to progress proprietary drug candidates through pre-clinical and early clinical stages within Australia.

Neuroscientific Biopharmaceuticals Ltd (NSB) is an Australian clinical-stage pharmaceutical company focused on developing novel peptide-based drugs for neurological and neurodegenerative disorders. Their lead drug candidate, EmtinB, targets conditions such as Alzheimer's disease, Multiple Sclerosis, and glaucoma, aiming to address significant unmet medical needs. The company is advancing its proprietary therapeutic compounds through various stages of preclinical and clinical development.